La start-up tricolore est à l’origine d’une plateforme d’IA et de robotique visant à accélérer la découverte de nouveaux médicaments en oncologie et en neurologie. Elle devrait mettre au point de peti...

PRESS RELEASE Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery Synsight provides Iktos with an exclusive worldwide license to INSERM’s patented technology…

Le Dîner-Débat 2025 de l'Unafic aura lieu le jeudi 13 novembre à 18h à Chimie Paris, sur la thématique :   "Robotique et Intelligence Artificielle :révolution dans l’industrie chimique ?"   Les inscr...

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor

L'intelligence artificielle s'impose dans la recherche pharmaceutique française. Les laboratoires Pierre Fabre et la biotech Iktos ont décidé de s'associer pour découvrir des molécules contre le cance...

By Yann Gaston-Mathé, CEO at iktos Medicinal chemistry has long been regarded as a meticulous craft, blending empirical knowledge with innovative experimentation to transform natural substances into...

Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug ... Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, synthesize, and optimize ...

Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug ... Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, synthesize, and optimize ...

CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ — Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies’ commitment to advancing oncology research by integrating complementary strengths […]

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

Plus, news about Catalio Capital, Rapport, Servier and Iktos, as well as Century, among others

La IA accelera la cursa per nous medicaments: França vol jugar a la primera divisió. Start-up com Owkin, Aqemia, Iktos o WhiteLab Genomics situen França al mapa global de la IA aplicada a la salut, un...

Pierre Fabre Laboratories and Iktos have announced a groundbreaking collaboration aimed at integrating AI for drug discovery in oncology, focusing on developing new low-molecular-weight drug candidates.

Pierre Fabre Laboratories collaborates with Iktos to accelerate drug discovery in oncology using AI, showcasing their commitment to advancing cancer research.

Pierre Fabre Laboratories and Iktos have formed a cutting-edge AI-focused collaboration aimed at enhancing drug discovery in oncology, utilizing advanced generative design technology.

Pierre Fabre and Iktos announce a groundbreaking collaboration leveraging AI for drug discovery in oncology, enhancing treatment options for patients.